External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ESMO IO 2022
Roche and Genentech at

ESMO IO 2022

December 07 - December 09
Geneva, Switzerland & Online
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
02:43 PM
Duration 10mins Room B
IMpower010: ctDNA status in patients (pts) with NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
E. Felip, M. K. Srivastava, M. Reck, H. Wakelee, N. Altorki, E. Vallieres, R. Liersch, M. Harada, H. Tanaka, J. T. Hamm, S. McCune, E. Bennett, B. Gitlitz, V. McNally, S. Novella, M. Ballinger, W. Zou, B. Y. Nabet, M. Das Thakur, C. Zhou
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 AM
Duration 5mins Room C
IMscin001 (Part 2: Randomized Phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Burotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, Herraez-Baranda L, Liu S, Chan P, Shearer-Kang E, Shivhare M, Tosti N, Zanghi J, Leutgeb B, Felip E
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.